9.26
+0.005(+0.05%)
Currency In USD
| Previous Close | 9.25 |
| Open | 9.34 |
| Day High | 9.58 |
| Day Low | 9.24 |
| 52-Week High | 13.53 |
| 52-Week Low | 5.64 |
| Volume | 279,350 |
| Average Volume | 2.47M |
| Market Cap | 950.26M |
| PE | -6.09 |
| EPS | -1.52 |
| Moving Average 50 Days | 8.78 |
| Moving Average 200 Days | 7.44 |
| Change | 0.01 |
If you invested $1000 in Day One Biopharmaceuticals, Inc. (DAWN) since IPO date, it would be worth $393.83 as of January 09, 2026 at a share price of $9.255. Whereas If you bought $1000 worth of Day One Biopharmaceuticals, Inc. (DAWN) shares 3 years ago, it would be worth $422.8 as of January 09, 2026 at a share price of $9.255.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Day One Completes Acquisition of Mersana Therapeutics
GlobeNewswire Inc.
Jan 06, 2026 2:02 PM GMT
Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting rare cancer adenoid cystic carcinoma (ACC)BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 16, 2025 1:30 PM GMT
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
GlobeNewswire Inc.
Nov 24, 2025 1:00 PM GMT
Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least 12 months The median time to nex